Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Castration-Sensitive Prostate Carcinoma”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Looking for participantsNCT06378866
What this trial is testing

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Who this might be right for
Recurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate CancerCastration-resistant Prostate Cancer+1 more
Mayo Clinic 532
Testing effectiveness (Phase 2)Ended earlyNCT03810105
What this trial is testing

Olaparib and Durvalumab in Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 5
Early research (Phase 1)Looking for participantsNCT05997615
What this trial is testing

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Vir Biotechnology, Inc. 390
Testing effectiveness (Phase 2)Looking for participantsNCT04550494
What this trial is testing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+28 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT02020070
What this trial is testing

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center 16
Not applicableLooking for participantsNCT06835218
What this trial is testing

PROCARE - PROstate Cancer Real World Evidence Registry

Who this might be right for
Prostate CancerBiochemical Recurrence of Malignant Neoplasm of ProstateNon-metastatic Castration-resistant Prostate Cancer+2 more
UroTrials Company (GmbH) 5,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06654336
What this trial is testing

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Who this might be right for
Prostate AdenocarcinomaCastration Sensitive Prostate Cancer
Ontario Clinical Oncology Group (OCOG) 162
Early research (Phase 1)Active Not RecruitingNCT06555796
What this trial is testing

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Who this might be right for
Prostate CancerHigh-risk Biochemical RecurrenceHigh Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer+1 more
Amgen 50